Intra-Cellular Therapies, Inc. (ITCI)
NASDAQ: ITCI · Real-Time Price · USD
126.20
-0.06 (-0.05%)
At close: Jan 17, 2025, 4:00 PM
126.08
-0.13 (-0.10%)
After-hours: Jan 17, 2025, 5:47 PM EST
Intra-Cellular Therapies Stock Forecast
Stock Price Forecast
The 13 analysts with 12-month price forecasts for ITCI stock have an average target of 100.31, with a low estimate of 74 and a high estimate of 132. The average target predicts a decrease of -20.52% from the current stock price of 126.20.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for ITCI stock from 13 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
---|---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 5 | 5 | 4 |
Buy | 4 | 4 | 5 | 5 | 5 | 5 |
Hold | 2 | 2 | 2 | 2 | 2 | 4 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 11 | 11 | 12 | 12 | 12 | 13 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Piper Sandler | Piper Sandler | Buy → Hold Downgrades $107 → $132 | Buy → Hold | Downgrades | $107 → $132 | +4.60% | Jan 14, 2025 |
Needham | Needham | Strong Buy → Hold Downgrades $100 | Strong Buy → Hold | Downgrades | $100 | -20.76% | Jan 13, 2025 |
JP Morgan | JP Morgan | Buy Maintains $81 → $89 | Buy | Maintains | $81 → $89 | -29.48% | Nov 4, 2024 |
Needham | Needham | Strong Buy Reiterates $100 | Strong Buy | Reiterates | $100 | -20.76% | Oct 31, 2024 |
Needham | Needham | Strong Buy Reiterates $100 | Strong Buy | Reiterates | $100 | -20.76% | Oct 30, 2024 |
Financial Forecast
Revenue This Year
689.19M
from 464.37M
Increased by 48.41%
Revenue Next Year
952.84M
from 689.19M
Increased by 38.26%
EPS This Year
-0.71
from -1.46
EPS Next Year
0.38
from -0.71
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | 715.1M | 1.1B | 1.7B | |||
Avg | 689.2M | 952.8M | 1.5B | |||
Low | 656.2M | 839.9M | 1.1B |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | 54.0% | 55.4% | 82.5% | |||
Avg | 48.4% | 38.3% | 52.4% | |||
Low | 41.3% | 21.9% | 15.5% |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | -0.37 | 1.39 | 6.33 | |||
Avg | -0.71 | 0.38 | 3.81 | |||
Low | -1.04 | -0.92 | 1.46 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | - | - | 1,555.9% | |||
Avg | - | - | 895.3% | |||
Low | - | - | 281.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.